Telephone sharing button Contact Us mailbox sharing button
arrow_left sharing button
arrow_right sharing button

Services & Solutions

Bioconjugation Discovery

Extensive R&D capabilities and world-class expertise


Extensive R&D capabilities and world-class expertise is available at WuXi XDC to generate, engineer, evaluate and optimize antibody drug conjugate (ADC)/bioconjugate lead candidates including trouble-shooting and overcoming the challenges associated with complex bioconjugated moieties. Wide-ranging R&D of the bioconjugation key intermediates including mAb/protein, payload and linkers. is also available and is a cornerstone of the WuXi XDC technology platform.

Bioconjugation Discovery Services & Capabilities Overview

High-throughput Conjugation Screening

To maximize the efficiency of your drug discovery efforts, we use a state-of-the-art high-throughput ADC conjugation platform and a highly vetted project management system to facilitate ADC candidate selection. We utilize a Design of Experiment (DOE) matrix approach utilizing high-throughput (HTP) methodologies for the generation and evaluation of the intermediates and conjugates from microgram to milligram scale. In the example to the right, IgGs from hybridoma crude culture media, regardless of their concentrations, can be made into ADCs of the same DAR (tunable from DAR2-DAR4 and with low residual free drug) for the ensuing batch analyses and selections of ADC preclinical candidates.

Conjugation Capabilities

The discovery services team at WuXi XDC applies multiple methods for the synthesis of bioconjugates between payloads and macromolecules that include proteins (e.g., antibodies, fusion proteins), peptides, and polynucleotides, amongst others. We use many types of conjugation technologies including traditional cysteine- and lysine-conjugation, and many of the widely used site-directed conjugation methods such as THIOMAB™, non-natural amino acid incorporation, and glycol site- and enzyme-assisted conjugation. Our bioconjugation experience encompasses multiple carriers and an extensive linker and payload library is available for your R&D purposes as demonstrated in the table:

Novel Technologies

Antibody and payload conjugation development utilizing multiple technologies including WuXi XDC proprietary technologies (e.g., WuXiDAR4TM Drug Antibody Ratio Technology Platform) is available from our large team of highly trained scientists.


WuXiDAR4 is a novel technology platform to overcome the challenges of ADC heterogeneity and therefore establish uniform DAR in ADCs. The WuXiDAR4 technology comprises two methods to increase the DAR4 percentage from 85% to 90% in cysteine-conjugated ADCs. WuXiDAR4 ADCs, rivaling site-directed bioconjugates, show better PK and efficacy than traditional cysteine-conjugated ADCs.

Diagnostic and Imaging Reagents

WuXi XDC supports research, development and manufacture of labeled antibodies for in vitro and in vivo studies and for use in diagnostic kits. Our experience with labels includes a variety of fluorescent tags, HRP, and biotin amongst others. In addition, we have ready-made secondary antibodies with signal amplification and sensitivity rivaling other commercially available options.


In the example to the right, secondary antibodies developed at WuXi XDC are used in 2-step staining for antigen detection in formalin-fixed and paraffin-embedded tissues and are not interfered with by endogenous biotin in the staining samples. The labeled antibodies are compatible with primary antibodies of mouse or rabbit origins and provide industry-standard signal amplification magnitudes.


You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?